Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach
Purpose of Review
With recent cardiovascular outcome trial (CVOT) results for antihyperglycemic medications, the treatment algorithm for patients with type 2 diabetes (T2DM) and atherosclerotic vascular disease (ASCVD) requires revision.
All completed CVOTs have demonstrated CV safety of the tested medications, with some trials demonstrating CV efficacy. While metformin remains the first-line recommended medication for T2DM, 18–37% of the patients enrolled in the completed CVOTs were not treated with metformin, providing substantial power to assess CV outcomes independent of metformin. The safety and tolerability of metformin are indisputable, but there are no robust data proving its efficacy for either macro or microvascular disease outcomes. We should reconsider the primacy of metformin in the management of T2DM in patients with ASCVD.
This article will review the evidence for CV effects of antihyperglycemic agents (AHAs), and propose an evidence-based treatment algorithm for patients with T2DM and ASCVD.
KeywordsType 2 diabetes Atherosclerotic cardiovascular disease Coronary artery disease HbA1c Metformin Cardiovascular outcomes trials
Compliance with Ethical Standards
Conflict of Interest
Josephine L. Harrington, Natalia de Albuquerque Rocha, and Kershaw V. Patel declare that they have no conflict of interest.
Subodh Verma has received support from Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, and Sanofi.
Darren K. McGuire has received support for clinical trial leadership from AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, Esperion; and honoraria for consultancy from AstraZeneca, Sanofi Aventis, Lilly US, Boehringer Ingelheim, Merck & Co, Pfizer, Metavant, and Novo Nordisk.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.National Diabetes Statistics Report. | Data & Statistics | Diabetes | CDC. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed 24 Mar 2018.
- 3.Roglic G, World Health Organization Global report on diabetes. World Health Organization, Geneva, Switzerland. http://www.who.int/diabetes/global-report/en/. Accessed 24 Mar 3018.
- 4.Patel A, MacMahon S, on behalf of the ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358:2560–72.Google Scholar
- 9.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:837–53.Google Scholar
- 14.Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 19:Suppl:789–830.Google Scholar
- 20.•• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–28. CVOT showing CV superiority for empagliflozin, an SGLT2i Google Scholar
- 21.•• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377:644–57. CVOT showing CV superiority for canagliflozin, an SGLT2i Google Scholar
- 22.•• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 375:311–22. CVOT showing CV superiority for liraglutide, a GLP-1RA Google Scholar
- 23.•• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 375:1834–44. CVOT showing CV superiority for semaglutide, a GLP-1RA. Google Scholar
- 24.Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358:2545–59.Google Scholar
- 26.• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 Diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38:140–9. Current Guidelines on T2DM management by the American Diabetes Association and European Association for the Study of Diabetes Google Scholar
- 27.• AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm 2018. In: Am. Assoc. Clin. Endocrinol. https://www.aace.com/publications/algorithm. Accessed 2 Apr 2018 Current Guidelines on T2DM management by the American Association of Endocrinologists and American College of Endocrinology.
- 28.• International Diabetes Federation. Global Guideline for Type 2 Diabetes. https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. Accessed 6 Apr 2018 Current Guidelines on T2DM management by the International Diabetes Federation.
- 30.• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet Lond Engl. 1998;352:854–65. Study that suggested that there was a decrease in MI and CV mortality rate in patients randomized to metformin. This study played a large role in metformin’s ubiquity CrossRefGoogle Scholar
- 36.Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev CD002967.Google Scholar
- 38.• Diabetes Canada | Clinical Practice Guidelines - 2018 Full Guidelines. http://guidelines.diabetes.ca/fullguidelines. Accessed 9 May 2018. Current guidelines on T2DM management by Diabetes Canada.
- 41.U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 26 Apr 2018.
- 42.WHO | WHO Model Lists of Essential Medicines. In: WHO. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 27 Apr 2018.
- 44.• Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9:e1001204. A meta-analysis of metformin trials (including UKPDS 34) that was unable to exclude reductions or increases in all-cause mortality or CV mortality associated with metformin use.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Standards of Medical Care in Diabetes | American Diabetes Association. https://professional.diabetes.org/content-page/standards-medical-care-diabetes. Accessed 9 May 2018.
- 57.Bergmark BA, Bhatt DL, McGuire D, et al. Abstract 16764: metformin use and clinical outcomes among patients with diabetes mellitus and heart failure or kidney dysfunction—observations from the SAVOR-TIMI 53 trial. Circulation. 2016;134:A16764.Google Scholar
- 58.Crowley MJ, Williams JW, Kosinski AS, D’Alessio DA, Buse JB. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care. 2017; https://doi.org/10.2337/dc17-1528.
- 59.U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed 31 Mar 2018.
- 60.U.S. Food and Drug Administration. Victoza (liraglutide [rDNA origin] injection. Package Insert.Google Scholar
- 61.Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet Lond Engl. 2005;366:1279–89.CrossRefGoogle Scholar
- 65.Scirica BM, Braunwald E, Raz I et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 Randomized Trial. Circulation CIRCULATIONAHA.114.010389.Google Scholar
- 67.Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877–86.CrossRefPubMedGoogle Scholar
- 69.Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and renal microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17:39.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016; https://doi.org/10.1186/s12933-016-0357-x.
- 76.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefPubMedGoogle Scholar
- 77.Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.CrossRefPubMedGoogle Scholar